Articles with the topic: featured

The director’s cut: how CAG repeats change the editing of genetic messages

The director’s cut: how CAG repeats change the editing of genetic messages

Scientists in Massachusetts have recently advanced our understanding of how repetitive sequences in DNA can disrupt the creation and editing of genetic messenger molecules in cells, and how this could lead to the production of harmful proteins.

Lucy CouplandMarch 26, 2024

Understanding expansions at the single cell level

Understanding expansions at the single cell level

Scientists have looked at CAG expansions in brains from people with HD to see which cells are affected

Dr Rachel HardingMarch 12, 2024

Huntington's Disease Therapeutics Conference 2024 - Day 3

Huntington's Disease Therapeutics Conference 2024 - Day 3

Dr Rachel Harding, Dr Leora Fox, and Dr Sarah HernandezMarch 07, 2024

Huntington's Disease Therapeutics Conference 2024 - Day 2

Huntington's Disease Therapeutics Conference 2024 - Day 2

Dr Leora Fox, Dr Sarah Hernandez, and Dr Rachel HardingMarch 06, 2024

Huntington's Disease Therapeutics Conference 2024 - Day 1

Huntington's Disease Therapeutics Conference 2024 - Day 1

Check out research updates from Day 1 of the 2024 HD Therapeutics Conference #HDTC2024

Dr Leora Fox, Dr Rachel Harding, and Dr Sarah HernandezMarch 05, 2024

CRISPR-based drugs: one giant leap for mankind

CRISPR-based drugs: one giant leap for mankind

Casgevy is the first CRISPR-based drug to make its way through the approval process, all but curing Sickle Cell Disease and it’s paving the way for similar drugs targeting other diseases. Is Huntington’s disease next?

Dr Sarah HernandezFebruary 14, 2024

Steady progress from uniQure - promising data to end the year

Steady progress from uniQure - promising data to end the year

uniQure ushered in the end of the year by releasing some promising data from their huntingtin-lowering gene therapy trials

Dr Leora FoxDecember 20, 2023

Putting it in print: GENERATION HD1 study results published

Putting it in print: GENERATION HD1 study results published

Data from GENERATION HD1, the Phase 3 clinical trial testing the huntingtin-lowering drug tominersen, have just been published in a scientific journal. The trial ended a while back, so why is this an important milestone, and what’s next?

Dr Leora Fox, Dr Rachel Harding, and Dr Sarah HernandezDecember 07, 2023

Regulating repetition: Gaining control of CAG repeats could slow progression of Huntington’s disease

Regulating repetition: Gaining control of CAG repeats could slow progression of Huntington’s disease

Many diseases are caused by repetitive DNA sequences. Understanding the regulation of those repetitive sequences may hold the key for unlocking therapeutics for Huntington’s disease. A team from Toronto has just advanced our understanding.

Dr Sarah HernandezNovember 30, 2023